Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ABT Abbott $69.86 1.14 (1.66%) , BSX Boston Scientific $37.64 1.21 (3.32%) … 10:23 10/16/18 10/16 10:23 10/16/18 10:23 Initiation	On The Fly: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abbott (ABT), Boston Scientific (BSX), Stryker (SYK), and Medtronic (MDT) were initiated with an Overweight at Barclays, while Baxter (BAX), Edwards Lifesciences (EW), and Zimmer Biomet (ZBH) were initiated with an Underweight. 2. Expedia (EXPE) was initiated with an Outperform at Evercore ISI, while TripAdvisor (TRIP) was initiated with an In Line, and Booking Holdings (BKNG) was initiated with an In Line. 3. Facebook (FB) was initiated with a Buy at Loop Capital and Rosenblatt. 4. Snap (SNAP) initiated with a Hold at Loop Capital. 5. VF Corp. (VFC) initiated with a Neutral at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. ABT Abbott $69.86 1.14 (1.66%) BSX Boston Scientific $37.64 1.21 (3.32%) SYK Stryker $172.45 3.03 (1.79%) MDT Medtronic $95.39 1.58 (1.68%) BAX Baxter $71.00 0.12 (0.17%) EW Edwards Lifesciences $144.31 2.36 (1.66%) ZBH Zimmer Biomet $124.31 0.72 (0.58%) EXPE Expedia $120.28 1.73 (1.46%) TRIP TripAdvisor $46.17 1.17 (2.60%) BKNG Booking Holdings $1,824.49 12.59 (0.69%) FB Facebook $156.16 2.6 (1.69%) SNAP Snap $7.23 -0.18 (-2.43%) VFC VF Corp. $88.01 0.36 (0.41%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	16 Oct 17 Oct 19 Oct 19 Oct 19 Oct 23 Oct 23 Oct 24 Oct 25 Oct 25 Oct 25 Oct 26 Oct 28 Oct 30 Oct 31 Oct 05 Nov 07 Nov 08 Nov 13 Nov 15 Nov
ABT Abbott $68.72 -0.62 (-0.89%) , SYK Stryker $169.42 -1.66 (-0.97%) … 06:53 10/16/18 10/16 06:53 10/16/18 06:53 Initiation	Abbott, Stryker, Medtronic, Baxter, Edwards Lifesciences, Zimmer Biomet, Boston Scientific initiated at Barclays » Barclays starts MedTech… Barclays starts MedTech sector with Positive view. Barclays analyst Kristen Stewart last night initiated coverage of the MedTech sector with a Positive view. The analyst expects the MedTech market to grow 4%-5% "for the foreseeable future" and believes the recent increase in price-to-earnings multiples in the space is warranted given the improving fundamentals. Looking ahead, she thinks relative P/E multiples "should be at least maintained." Stewart initiated coverage on 12 stocks, with Overweight ratings on Abbott (ABT), Boston Scientific (BSX) Stryker (SYK) and Medtronic (MDT). The analyst put Underweight ratings on Baxter (BAX), Edwards Lifesciences (EW) and Zimmer Biomet (ZBH). ABT Abbott $68.72 -0.62 (-0.89%) SYK Stryker $169.42 -1.66 (-0.97%) MDT Medtronic $93.81 -0.85 (-0.90%) BAX Baxter $70.88 -0.39 (-0.55%) EW Edwards Lifesciences $141.95 -1.44 (-1.00%) ZBH Zimmer Biomet $123.59 0.12 (0.10%) BSX Boston Scientific $36.43 -0.56 (-1.51%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Oct 19 Oct 19 Oct 23 Oct 23 Oct 24 Oct 25 Oct 26 Oct 31 Oct

Yesterday
BSX Boston Scientific $36.43 -0.56 (-1.51%) 17:26 10/15/18 10/15 17:26 10/15/18 17:26 Initiation	Boston Scientific initiated at Barclays » Boston Scientific… Boston Scientific initiated with an Overweight at Barclays. Barclays analyst Kristen Stewart initiated Boston Scientific with an Overweight rating and $43 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Oct
BSX Boston Scientific $36.99 1 (2.78%) 07:51 10/15/18 10/15 07:51 10/15/18 07:51 Recommendations	Boston Scientific analyst commentary at RBC Capital » Boston Scientific price… Boston Scientific price target raised to $42 from $36 at RBC Capital. RBC Capital analyst Glenn Novarro raised his price target on Boston Scientific to $42 and kept his Top Pick rating, saying the first-half momentum in the Medical Surgery, Rhythm & Neuro, and Cardiovascular segments should persist in Q3. The analyst expects the company's operational growth to be around 8% in the quarter and potentially as high as 10% in 2019-2020. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Oct

Over a week ago
BSX Boston Scientific $37.31 -0.54 (-1.43%) , ISRG Intuitive Surgical $526.51 -22.44 (-4.09%) … 07:51 10/09/18 10/09 07:51 10/09/18 07:51 Recommendations	Boston Scientific, Intuitive Surgical, Becton Dickinson, Varian Medical, Edwards Lifesciences, Baxter, Zimmer Biomet analyst commentary at Citi » Citi more selective on… Citi more selective on Medical Device stocks into Q3 results. Citi analyst Amit Hazan is "much more selective than usual" on Medical Device stocks into the Q3 earnings season. While easier comps should bring "strong and stable" Q3 organic sales growth, recent currency volatility will limit both earnings upside and guidance raises, Hazan tells investors in a research note. He sees only Boston Scientific (BSX) and Intuitive Surgical (ISRG) shares moving higher on earnings reports. The analyst expects volatility in both Becton Dickinson (BDX) and Varian Medical (VAR), but would be an "aggressive" buyer of the stocks on any post-earnings weakness. Hazan is also more cautious on names like Edwards Lifesciences (EW), Baxter (BAX), and Zimmer Biomet (ZBH) into the Q3 prints. BSX Boston Scientific $37.31 -0.54 (-1.43%) ISRG Intuitive Surgical $526.51 -22.44 (-4.09%) BDX Becton Dickinson $250.34 -3.41 (-1.34%) VAR Varian Medical $107.71 -0.38 (-0.35%) EW Edwards Lifesciences $147.13 -4.57 (-3.01%) BAX Baxter $73.34 -0.84 (-1.13%) ZBH Zimmer Biomet $127.39 -1.2 (-0.93%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Oct 19 Oct 19 Oct 23 Oct 23 Oct 24 Oct 26 Oct 31 Oct 06 Nov

BSX Boston Scientific $38.98 0.5 (1.30%) 08:39 10/02/18 10/02 08:39 10/02/18 08:39 Recommendations	Boston Scientific analyst commentary at Morgan Stanley » Boston Scientific price… Boston Scientific price target raised to $48 from $38 at Morgan Stanley. Morgan Stanley analyst David Lewis raised his price target on Boston Scientific shares to $48 from $38 as he believes the company's recent deal activity reflects an accelerating M&A climate, maturing venture portfolio and upcoming access to $2B in annual free cash flow and does not suggest a weakening of its core business. His deal by deal analysis suggests management's assumptions for the contributions from M&A appear conservative, added Lewis, who keeps an Overweight rating on Boston Scientific. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Oct 24 Oct
TFX Teleflex $265.31 -3.62 (-1.35%) , BSX Boston Scientific $38.35 -0.28 (-0.72%) 08:18 09/28/18 09/28 08:18 09/28/18 08:18 Recommendations	Teleflex, Boston Scientific analyst commentary at Jefferies » Jefferies boosts… Jefferies boosts Teleflex, Boston Scientific targets after urologist survey. Jefferies analyst Raj Denhoy raised his estimates for Teleflex (TFX) and Boston Scientific (BSX) after conducting a survey of 50 U.S.-based urologists to better understand demand and utilization trends for Teleflex's recently acquired UroLift and Boston Scientific's recently acquired Rezum System. He found that UroLift is 15% of procedure mix and expected to reach 25% in two years, and that current mix for Rezum is 10% and expected to be 20% in two years. UroLift taking share from all other modalities including drug therapy while Rezum is gaining share from surgery/ablation, Denhoy tells investors in a research note. The analyst increased his price target for Teleflex to $300 and for Boston Scientific to $45. He keeps Buy rating on both stocks. TFX Teleflex $265.31 -3.62 (-1.35%) BSX Boston Scientific $38.35 -0.28 (-0.72%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Oct 08 Nov
ABT Abbott $71.43 2.38 (3.45%) , ABMD Abiomed $419.53 34.84 (9.06%) … 04:55 09/25/18 09/25 04:55 09/25/18 04:55 Conference/Events	Cardiovascular Research Foundation » TCT 2018 will be held in… TCT 2018 will be held in San Diego, CA on September 21-25. ABT Abbott $71.43 2.38 (3.45%) ABMD Abiomed $419.53 34.84 (9.06%) AMGN Amgen $207.30 2.25 (1.10%) AZN AstraZeneca $37.84 0.155 (0.41%) BSX Boston Scientific $38.39 0.63 (1.67%) CAE CAE $20.10 -0.345 (-1.69%) CAJ Canon $31.52 -0.165 (-0.52%) CSII Cardiovascular Systems $37.16 0.42 (1.14%) EW Edwards Lifesciences $165.52 11.81 (7.68%) HCA HCA Healthcare $134.31 0.95 (0.71%) ICLR Icon $149.62 -0.54 (-0.36%) LIVN LivaNova $124.79 2.46 (2.01%) MDT Medtronic $98.85 1 (1.02%) PHG Philips $45.68 -0.18 (-0.39%) REGN Regeneron $390.39 -0.16 (-0.04%) SNY Sanofi $43.40 -0.21 (-0.48%) SIEGY Siemens $0.00 (0.00%) TFX Teleflex $268.91 -0.84 (-0.31%) VBLT VBL Therapeutics $1.58 -0.025 (-1.56%) WTKWY Wolters Kluwer $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Sep 26 Sep 27 Sep 29 Sep 01 Oct 03 Oct 03 Oct 09 Oct 11 Oct 17 Oct 17 Oct 20 Oct 22 Oct 22 Oct 28 Oct 29 Oct 06 Nov 08 Nov 09 Nov 27 Nov 28 Jan 22 Mar 28 Apr 13 May
BSX Boston Scientific $38.37 0.61 (1.62%) 15:05 09/24/18 09/24 15:05 09/24/18 15:05 Options	Boston Scientific call volume above normal and directionally bullish » Bullish option flow… Bullish option flow detected in Boston Scientific with 4,938 calls trading, 1.2x expected, and implied vol increasing over 2 points to 25.35%. Oct-18 38 calls and Oct-18 38.5 calls are the most active options, with total volume in those strikes near 2,100 contracts. The Put/Call Ratio is 0.28. Earnings are expected on October 25th. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Sep 09 Oct
JNJ Johnson & Johnson $140.70 -2.15 (-1.51%) , BSX Boston Scientific $38.33 0.57 (1.51%) … 14:05 09/24/18 09/24 14:05 09/24/18 14:05 Periodicals	J&J may be interested in Boston Scientific, Edwards Lifesciences, Barron's says » According to an earlier… According to an earlier story from Barron's, Wells Fargo analyst Larry Biegelsen's speculated that drug giant Johnson & Johnson (JNJ) may be interested in acquiring "Boston Scientific (BSX) or its heart-valve rival, Edwards Lifesciences (EW)." Either acquisition "would make sense" according to the analyst's September 16 note, says Barron's. According to Barron's the analyst observed that devices accounted for 41% of J&J's total sales in 2012 but are expected to generate only 32% in 2019. Reference Link JNJ Johnson & Johnson $140.70 -2.15 (-1.51%) BSX Boston Scientific $38.33 0.57 (1.51%) EW Edwards Lifesciences $165.13 11.42 (7.43%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Sep 09 Oct 16 Oct 28 Oct

On The Fly

News and insights, exclusive to thefly.com

13:31	Game On: Pachter says 'Red Dead Online' could be 25% as popular as 'GTA Online'»
13:19	Fly Intel: What to watch for in IBM's earnings report»
12:56	Game On: Benchmark's Hickey calls new 'COD' battle royale mode 'a game changer'»
12:46	Notable companies reporting before tomorrow's open»
12:46	Notable companies reporting after market close»

View all On The Fly Stories »

Upcoming
Events (10)

ITUS	Pre-IND Meeting with FDA & ITUS Corp
	Fuel Oil Summit
	Adobe MAX
A ...	ASHG Conference 2018
	2018 HCIT & Distribution Roundtable
	Gartner Symposium: ITxpo 2018
	Teradata Analytics Universe
	3-D Printing Field Trip
GNTX ...	NBAA Business Aviation Convention & Exhibition (NBAA-BACE)
XLNX ...	Arm TechCon 2018

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals for your search.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial